MedPath

Adjunctive Ganglionated Plexus Ablation in Redo-Pulmonary Vein Isolation

Not Applicable
Active, not recruiting
Conditions
Atrial Fibrillation
Paroxysmal Atrial Fibrillation
Interventions
Procedure: Radiofrequency ablation
Registration Number
NCT03535818
Lead Sponsor
Imperial College London
Brief Summary

The investigator propose to test the efficacy of adjunctive ET-GP ablation in patients undergoing redo PVI for paroxysmal AF.

Detailed Description

Patients with ongoing paroxysmal arrhythmias after pulmonary vein isolation (PVI) for paroxysmal and persistent atrial fibrillation (AF) get incrementally less benefit with redo-PVI. This implies non-pulmonary vein (PV) triggers, which are more challenging to locate. The autonomic nervous system is implicated in the multifactorial pathogenesis of AF but few studies have attempted neural targeting as a therapeutic intervention. We have demonstrated that stimulation of specific left atrial ganglionated plexi (GPs) triggers both AF and atrial ectopy and importantly stimulation of these sites may not induce AV block, the 'conventional' marker used to locate GPs. Having shown that these ectopy-triggering GP (ET-GP) sites are anatomically stable and can be rendered inactive by either ablation at the site or by ablation between the site and the adjacent PV, a single centre study suggests that ET-GP ablation can prevent recurrent AF in some patients.

Recruitment & Eligibility

Status
ACTIVE_NOT_RECRUITING
Sex
All
Target Recruitment
68
Inclusion Criteria
  • Males or females eighteen (18) to eighty five (85) years old
  • Paroxysmal atrial fibrillation
  • Previous pulmonary vein isolation
  • Suitable candidate for catheter ablation
  • Signed informed consent
Read More
Exclusion Criteria
  • Contraindication to catheter ablation
  • Presence of a cardiac thrombus
  • Valvular disease that is grade moderate or greater
  • Any form of cardiomyopathy
  • On amiodarone therapy
  • Patients who lack capacity
  • Active gastrointestinal bleeding
  • Active infection or fever
  • Renal failure (Creatinine >200µmol/L)
  • Life expectancy shorter than the duration of the trial
  • Bleeding or clotting disorders or inability to receive heparin
  • Pregnant
Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Ganglionated plexus ablation + redo pulmonary vein isolationRadiofrequency ablation-
Redo pulmonary vein isolationRadiofrequency ablation-
Primary Outcome Measures
NameTimeMethod
Any atrial arrhythmia >30s documented on ECGs12 months

After blanking period 3 months

Secondary Outcome Measures
NameTimeMethod
Symptom recurrence requiring repeat ablations12 months
Radiofrequency timeWithin ablation procedure
Complications12 months

Trial Locations

Locations (1)

Prapa Kanagaratnam

🇬🇧

London, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath